Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Open Access
- 1 February 2023
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 369-373
- https://doi.org/10.2147/ccid.s403294
Abstract
The introduction of biologic drugs revolutionized the management of moderate-to-severe forms of psoriasis. However, safety concerns still remain, particularly on patient affected by opportunistic infections. In this scenario, the safety of biologic drugs in patient with HBV infection is debated. Globally, screening for hepatitis before starting biological treatment is mandatory as well as a referral to an infectivologist and eventual prophylactic management should be evaluated case by case, also considering risk factors. On the one hand, the use of anti-Tumor Necrosis Factor seems to increase the risk of HBV reactivation, conversely, the use of recently approved classes of biologics [anti-interleukin (IL) 17 and anti-IL23] seems to have a lower risk of HBV reactivation. However, the evidence on the safety of anti-IL23 drugs in patients affected by HBV is scant, particularly for patients undergoing treatment with tildrakizumab. Herein, we report the first case of a female patient affected by moderate-to-severe psoriasis and with chronic HBV infection undergoing prophylaxis, successfully treated with tildrakizumab without reporting hepatitis reactivation. Even if limited, our case seems to confirm available evidence about the safety of anti-IL23, particularly tildrakizumab, on patients with chronic HBV infection undergoing prophylaxis.Keywords
This publication has 30 references indexed in Scilit:
- Managing Psoriasis in Patients with HBV or HCV Infection: Practical ConsiderationsAmerican Journal of Clinical Dermatology, 2019
- An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysisJAAD Case Reports, 2019
- Safety of guselkumab in hepatitis B virus infectionDermatology Online Journal, 2019
- Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort StudyActa Dermato-Venereologica, 2018
- Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infectionDermatologic Therapy, 2018
- Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic ReviewBioDrugs, 2017
- Hepatitis B virus infectionThe Lancet, 2014
- Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 casesClinical Rheumatology, 2012
- Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted TherapyMedicine, 2011
- Psoriasis: epidemiologyClinics in Dermatology, 2007